Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 4/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327588 | 0.92 | TYK2 (0.37) | HRASKRASTYK2PDE4DKDM4E | |
| SCHEMBL26993043 | 0.81 | TYK2 (0.38) | TYK2 | |
| SCHEMBL23351255 | 0.80 | ALDH1A1 (0.32) | HRASKRASALDH1A1 | |
| SCHEMBL22092672 | 0.79 | TYK2 (0.47) | TYK2KDM4EALDH1A1L3MBTL1MAPT | |
| SCHEMBL23327537 | 0.78 | NR3C2 (0.38) | ZAP70KARS1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL23327768 | 0.78 | TYK2 (0.51) | TYK2PDE4DSTAT3 | |
| SCHEMBL29344717 | 0.77 | CDK2 (0.33) | HRASKRAS | |
| SCHEMBL29344696 | 0.77 | CRHR1 (0.33) | HRASKRAS | |
| SCHEMBL29344684 | 0.76 | POLB (0.30) | — | |
| SCHEMBL22092677 | 0.76 | TYK2 (0.44) | TYK2KDM4EALDH1A1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4054581-A1 | TYK2 PSEUDOKINASE LIGANDS | Ventyx Biosciences, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20210139486-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | TYK2, JAK1, JAK2 | HRAS 1909/4885KRAS 1934/4885TYK2 1/4885 |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | HRAS 479/4885KRAS 933/4885TYK2 1/4885 |
| US-20210139486-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | HRAS 479/4885KRAS 933/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.